https://mb.cision.com/Public/18595/3760134/903d0b2944774e2b_800x800ar.png
** UCB=E2=80=99s General Meeting of Shareholders 2023
------------------------------------------------------------
=C2=B7 For financial year 2022: Gross dividend of =E2=82=AC 1.33 per share =
(+ 2%), payable 03 May 2023
=C2=B7 All agenda items put to vote approved
=C2=B7 The message of Jean-Christophe Tellier, CEO of UCB is available on U=
CB=E2=80=99s global corporate website
Brussels (Belgium), 27 April 2023 =E2=80=93 18:00 (CEST) (regulated informa=
tion) =E2=80=93 Today, UCB held its Annual General Meeting of Shareholders =
(AGM). The company offered the choice to UCB shareholders to either partici=
pate in-person or to cast their vote by proxy. At the AGM, 81,04% of shares=
entitled to vote were represented.=C2=A0
The message of Mr. Jean-Christophe Tellier, Chief Executive Officer of UCB,=
published at the occasion of this general meeting, is available on the UCB=
website (https://www.ucb.com/investors/UCB-shareholders/Shareholders-meeti=
ng-2023) .
During his speech, Mr. Tellier commented: =E2=80=9C2022 was a challenging y=
ear where we faced headwinds but also garnered notable successes. This has =
enabled us to move into 2023 with a strong pipeline, a record number of pot=
ential medicines that are undergoing regulatory review and a string of pote=
ntial launches to come in numerous indications. We started well into the ye=
ar 2023 and are aligned with our financial guidance 2023. Looking at UCB to=
day, we have built solid foundations, allowing us to focus on the execution=
of our strategy and launch the medicines that will sustain our growth in t=
he coming years.=E2=80=9D=C2=A0
The AGM approved for the fiscal year 2022 the payment of a gross dividend o=
f =E2=82=AC 1.33 per share (net dividend of =E2=82=AC 0.931 per share) comp=
ared to =E2=82=AC 1.30 per share for 2021 (net =E2=82=AC 0.91). The ex-divi=
dend date is 28 April 2023, the dividend (coupon no. 26) will be payable as=
of 03 May 2023.
During the AGM, several renewals of members of the Board composition were a=
pproved. The AGM renewed the mandates of Mrs. Jan Berger as independent dir=
ector for a term of 4 years and the mandate of Mr. Cyril Janssen as directo=
r for a term of 4 years. Mrs. Viviane Monges stepped down from the Board of=
Directors and Audit Committee. To replace her, the AGM approved for a term=
of 4 years the appointment of Mrs. Ma=C3=ABlys Castella as new independent=
director. Mrs. Castella is a seasoned finance and business leader in areas=
including Strategy, Sustainability, Finance and Innovation. Mrs. Ma=C3=ABl=
ys Castella also replaces Mrs. Viviane Monges as member of the Audit Commit=
tee.
For the curriculum vitae of the Board members, please visit the UCB website=
: https://www.ucb.com/investors/UCB-governance (https://www.ucb.com/investo=
rs/UCB-governance.) .=C2=A0
All other agenda items put to vote at the AGM were approved by the sharehol=
ders. More information including details of the votes will be available soo=
n on UCB's website (https://www.ucb.com/investors/UCB-shareholders/Sharehol=
ders-meeting-2023) .
The Integrated Annual Report 2022 of UCB can be downloaded on UCB's website=
at https://www.ucb.com/investors/Download-center or is available on the on=
line portal at https://reports.ucb.com/.
The financial results for the first half year 2023 will be published on 27 =
July 2023.=C2=A0
Next year's General Meeting will be held on 25 April 2024.
For further information, contact UCB:=C2=A0
Investor Relations
Antje Witte
Investor Relations, UCB
T +32.2.559.9414
antje.witte@ucb.com=C2=A0
Global Communications=C2=A0
Laurent Schots
Media Relations, UCB
T+32.2.559.9264
Laurent.schots@ucb.com =C2=A0
About UCB=C2=A0
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 8 700 peopl=
e in 36 countries, the company generated revenue of =E2=82=AC 5.5 billion i=
n 2022. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twit=
ter: @UCB_news
Forward looking statements=C2=A0
This press release contains forward-looking statements including, without l=
imitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, =E2=
=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=9D, =E2=80=9Cintends=E2=
=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestimate=
s=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=E2=80=9D, =E2=80=9Ccontinu=
e=E2=80=9D and similar expressions. These forward-looking statements are ba=
sed on current plans, estimates and beliefs of management. All statements, =
other than statements of historical facts, are statements that could be dee=
med forward-looking statements, including estimates of revenues, operating =
margins, capital expenditures, cash, other financial information, expected =
legal, arbitration, political, regulatory or clinical results or practices =
and other such estimates and results. By their nature, such forward-looking=
statements are not guarantees of future performance and are subject to kno=
wn and unknown risks, uncertainties and assumptions which might cause the a=
ctual results, financial condition, performance or achievements of UCB, or =
industry results, to differ materially from those that may be expressed or =
implied by such forward-looking statements contained in this press release.=
Important factors that could result in such differences include: the globa=
l spread and impact of pandemics (such as COVID-19), wars on territories wh=
ere UCB has businesses, changes in general economic, business and competiti=
ve conditions, the inability to obtain necessary regulatory approvals or to=
obtain them on acceptable terms or within expected timing, costs associate=
d with research and development, changes in the prospects for products in t=
he pipeline or under development by UCB, effects of future judicial decisio=
ns or governmental investigations, safety, quality, data integrity or manuf=
acturing issues; potential or actual data security and data privacy breache=
s, or disruptions of our information technology systems, product liability =
claims, challenges to patent protection for products or product candidates,=
competition from other products including biosimilars, changes in laws or =
regulations, exchange rate fluctuations, changes or uncertainties in tax la=
ws or the administration of such laws, and hiring and retention of its empl=
oyees. There is no guarantee that new product candidates will be discovered=
or identified in the pipeline, or that new indications for existing produc=
ts will be developed and approved. Movement from concept to commercial prod=
uct is uncertain; preclinical results do not guarantee safety and efficacy =
of product candidates in humans. So far, the complexity of the human body c=
annot be reproduced in computer models, cell culture systems or animal mode=
ls. The length of the timing to complete clinical trials and to get regulat=
ory approval for product marketing has varied in the past and UCB expects s=
imilar unpredictability going forward. Products or potential products which=
are the subject of partnerships, joint ventures or licensing collaboration=
s may be subject to disputes between the partners or may prove to be not as=
safe, effective or commercially successful as UCB may have believed at the=
start of such partnership. UCB=E2=80=99 efforts to acquire other products =
or companies and to integrate the operations of such acquired companies may=
not be as successful as UCB may have believed at the moment of acquisition=
. Also, UCB or others could discover safety, side effects or manufacturing =
problems with its products and/or devices after they are marketed. The disc=
overy of significant problems with a product similar to one of UCB=E2=80=99=
s products that implicate an entire class of products may have a material a=
dverse effect on sales of the entire class of affected products. Moreover, =
sales may be impacted by international and domestic trends toward managed c=
are and health care cost containment, including pricing pressure, political=
and public scrutiny, customer and prescriber patterns or practices, and th=
e reimbursement policies imposed by third-party payers as well as legislati=
on affecting biopharmaceutical pricing and reimbursement activities and out=
comes. Finally, a breakdown, cyberattack or information security breach cou=
ld compromise the confidentiality, integrity and availability of UCB=E2=80=
=99s data and systems.=C2=A0
Given these uncertainties, you should not place undue reliance on any of su=
ch forward-looking statements. There can be no guarantee that the investiga=
tional or approved products described in this press release will be submitt=
ed or approved for sale or for any additional indications or labelling in a=
ny market, or at any particular time, nor can there be any guarantee that s=
uch products will be or will continue to be commercially successful in the =
future.
UCB is providing this information, including forward-looking statements, on=
ly as of the date of this press release and expressly disclaims any duty to=
update any information contained in this press release, either to confirm =
the actual results or to report or reflect any change in its forward-lookin=
g statements with regard thereto or any change in events, conditions or cir=
cumstances on which any such statement is based, unless such statement is r=
equired pursuant to applicable laws and regulations.=C2=A0
Additionally, information contained in this document shall not constitute a=
n offer to sell or the solicitation of an offer to buy any securities, nor =
shall there be any offer, solicitation or sale of securities in any jurisdi=
ction in which such offer, solicitation or sale would be unlawful prior to =
the registration or qualification under the securities laws of such jurisdi=
ction.
=C2=A0
GenericFile
UCB PR AGM 2023 PR ENG (https://mb.cision.com/Public/18595/3760134/ab9bc0c3=
aa5d1382.pdf) GenericFile
UCB PR AGM 2023 PR FR (https://mb.cision.com/Public/18595/3760134/b106ae8e6=
1828c87.pdf) GenericFile
UCB PR AGM 2023 PR NL (https://mb.cision.com/Public/18595/3760134/944428faf=
de56edd.pdf)
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x134987x1x6868579x2400=
0x6&Email=3Dregnews%40symexglobal.com.
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium
26/04/2024 20:00
25/04/2024 18:00
25/04/2024 07:01
23/04/2024 20:00
22/04/2024 07:01
19/04/2024 20:00
17/04/2024 07:01
12/04/2024 20:00
12/04/2024 18:01
12/04/2024 07:01